Gan & Lee Pharmaceuticals. (603087.SS)
| Previous Close | 34.92 |
| Open | 34.87 |
| Bid | 34.59 x N/A |
| Ask | 34.60 x N/A |
| Day's Range | 34.51 - 35.43 |
| 52 Week Range | 30.53 - 75.49 |
| Volume | |
| Avg. Volume | 5,018,241 |
| Market Cap | 19.424B |
| Beta (5Y Monthly) | 1.77 |
| PE Ratio (TTM) | 115.30 |
| EPS (TTM) | 0.30 |
| Earnings Date | Apr 29, 2022 - May 02, 2022 |
| Forward Dividend & Yield | 0.30 (0.88%) |
| Ex-Dividend Date | Jun 20, 2022 |
| 1y Target Est | N/A |
- ACCESSWIRE
Fortitude Gold Reports First Quarter Net Income Of $0.11 Per Share, Maintains 2022 Production Outlook
COLORADO SPRINGS, CO / ACCESSWIRE / May 4, 2022 / Fortitude Gold Corporation (OTCQB:FTCO) (the "Company") reported results for the first quarter ended March 31, 2022, including $15.3 million cash balance at quarter end.
- ACCESSWIRE
Fortitude Gold Reports Preliminary First Quarter Production Of 9,875 Gold Ounces
COLORADO SPRINGS, CO / ACCESSWIRE / April 18, 2022 / Fortitude Gold Corp. (OTCQB:FTCO) (the "Company") reports preliminary production results for the first quarter ended March 31, 2022 of 9,875 gold ounces.
- CNW Group
Gan & Lee Pharmaceuticals Begins First-In-Human Trial in U.S. for Investigational Drug, GZR18
Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), is pleased to announce the first subject has been dosed in our Phase I, double-blinded, randomized, placebo-controlled, sequential, single, ascending dose clinical study in the U.S. for the company's investigational drug, GZR18. GZR18 is a glucagon-like peptide-1 receptor agonist (GLP-1RA) with potential to treat patients with type 2 diabetes. Currently, type 2 diabetes mellitus accounts for approx
